Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
- PMID: 31099674
- DOI: 10.1200/EDBK_240837
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Abstract
The emergence of immune checkpoint blockade therapies over the last decade has transformed cancer treatment in a wide range of tumor types. Unprecedented and durable clinical responses in difficult-to-treat cancer histologies have been observed. However, despite these promising long-term responses, the majority of patients fail to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of those who initially respond to treatment eventually experience relapse secondary to acquired resistance. Both primary and acquired resistance are a result of complex and constantly evolving interactions between cancer cells and the immune system. Many mechanisms of resistance have been characterized to date, and more continue to be uncovered. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve clinical outcomes. This review will discuss the landscape of immune checkpoint blockade response data, different resistance mechanisms, and potential therapeutic strategies to overcome resistance.
Similar articles
-
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.Clin Cancer Res. 2018 Mar 15;24(6):1260-1270. doi: 10.1158/1078-0432.CCR-17-2267. Epub 2017 Nov 10. Clin Cancer Res. 2018. PMID: 29127120 Review.
-
Firing Up Cold Tumors.Trends Cancer. 2019 Sep;5(9):528-530. doi: 10.1016/j.trecan.2019.06.005. Epub 2019 Jul 13. Trends Cancer. 2019. PMID: 31474357 Review.
-
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.Front Immunol. 2018 Dec 21;9:3081. doi: 10.3389/fimmu.2018.03081. eCollection 2018. Front Immunol. 2018. PMID: 30627131 Free PMC article. Review.
-
Acquired resistance to cancer immunotherapy.Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2. Semin Immunopathol. 2019. PMID: 29968044 Review.
-
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.Cancer Med. 2018 Sep;7(9):4517-4529. doi: 10.1002/cam4.1722. Epub 2018 Aug 7. Cancer Med. 2018. PMID: 30088347 Free PMC article. Review.
Cited by
-
Mitochondrial Inhibition: a Treatment Strategy in Cancer?Curr Oncol Rep. 2021 Mar 17;23(4):49. doi: 10.1007/s11912-021-01033-x. Curr Oncol Rep. 2021. PMID: 33730242 Review.
-
Guidelines for immunological analyses following focused ultrasound treatment.J Immunother Cancer. 2023 Nov 24;11(11):e007455. doi: 10.1136/jitc-2023-007455. J Immunother Cancer. 2023. PMID: 38007236 Free PMC article.
-
Protein kinase Cι mediates immunosuppression in lung adenocarcinoma.Sci Transl Med. 2022 Nov 16;14(671):eabq5931. doi: 10.1126/scitranslmed.abq5931. Epub 2022 Nov 16. Sci Transl Med. 2022. PMID: 36383684 Free PMC article.
-
Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.Biomedicines. 2022 Oct 5;10(10):2481. doi: 10.3390/biomedicines10102481. Biomedicines. 2022. PMID: 36289743 Free PMC article.
-
Stem-like T cells and niches: Implications in human health and disease.Front Immunol. 2022 Aug 17;13:907172. doi: 10.3389/fimmu.2022.907172. eCollection 2022. Front Immunol. 2022. PMID: 36059484 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
